These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 26107755)
21. Clinicians' recognition of the metabolic adverse effects of antipsychotic medications. Buckley PF; Miller DD; Singer B; Arena J; Stirewalt EM Schizophr Res; 2005 Nov; 79(2-3):281-8. PubMed ID: 15964743 [TBL] [Abstract][Full Text] [Related]
22. A systematic review of metabolic side effects related to the use of antipsychotic drugs in dementia. Atti AR; Ferrari Gozzi B; Zuliani G; Bernabei V; Scudellari P; Berardi D; De Ronchi D; Tarricone I; Menchetti M Int Psychogeriatr; 2014 Jan; 26(1):19-37. PubMed ID: 24103643 [TBL] [Abstract][Full Text] [Related]
23. Metabolic risk factor profile associated with use of second generation antipsychotics: a cross sectional study in a Community Mental Health Centre. Tarricone I; Casoria M; Gozzi BF; Grieco D; Menchetti M; Serretti A; Ujkaj M; Pastorelli F; Berardi D BMC Psychiatry; 2006 Mar; 6():11. PubMed ID: 16542430 [TBL] [Abstract][Full Text] [Related]
24. Risperidone and Cardiometabolic Risk in Children and Adolescents: Clinical and Instrumental Issues. Matera E; Margari L; Palmieri VO; Zagaria G; Palumbi R; Margari F J Clin Psychopharmacol; 2017 Jun; 37(3):302-309. PubMed ID: 28338545 [TBL] [Abstract][Full Text] [Related]
25. Antipsychotics for children and young adults: a comparative effectiveness review. Seida JC; Schouten JR; Boylan K; Newton AS; Mousavi SS; Beaith A; Vandermeer B; Dryden DM; Carrey N Pediatrics; 2012 Mar; 129(3):e771-84. PubMed ID: 22351885 [TBL] [Abstract][Full Text] [Related]
26. [Metabolic risk during antipsychotic treatment in patients with schizophrenia]. Rzewuska M Psychiatr Pol; 2007; 41(4):457-72. PubMed ID: 18046977 [TBL] [Abstract][Full Text] [Related]
28. Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents. McIntyre RS; Jerrell JM Arch Pediatr Adolesc Med; 2008 Oct; 162(10):929-35. PubMed ID: 18838645 [TBL] [Abstract][Full Text] [Related]
29. Second-Generation Antipsychotics and Dysregulation of Glucose Metabolism: Beyond Weight Gain. Grajales D; Ferreira V; Valverde ÁM Cells; 2019 Oct; 8(11):. PubMed ID: 31671770 [TBL] [Abstract][Full Text] [Related]
30. Antipsychotics-induced metabolic alterations: focus on adipose tissue and molecular mechanisms. Gonçalves P; Araújo JR; Martel F Eur Neuropsychopharmacol; 2015 Jan; 25(1):1-16. PubMed ID: 25523882 [TBL] [Abstract][Full Text] [Related]
31. Differences in body mass index z-scores and weight status in a Dutch pediatric psychiatric population with and without use of second-generation antipsychotics. de Hoogd S; Overbeek WA; Heerdink ER; Correll CU; de Graeff ER; Staal WG J Child Adolesc Psychopharmacol; 2012 Apr; 22(2):166-73. PubMed ID: 22506734 [TBL] [Abstract][Full Text] [Related]
33. The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs. Falissard B; Mauri M; Shaw K; Wetterling T; Doble A; Giudicelli A; De Hert M Int Clin Psychopharmacol; 2011 Nov; 26(6):291-302. PubMed ID: 21876442 [TBL] [Abstract][Full Text] [Related]
34. The role of ghrelin signalling in second-generation antipsychotic-induced weight gain. Zhang Q; Deng C; Huang XF Psychoneuroendocrinology; 2013 Nov; 38(11):2423-38. PubMed ID: 23953928 [TBL] [Abstract][Full Text] [Related]
35. The effects of antipsychotic medications on microbiome and weight gain in children and adolescents. Bretler T; Weisberg H; Koren O; Neuman H BMC Med; 2019 Jun; 17(1):112. PubMed ID: 31215494 [TBL] [Abstract][Full Text] [Related]
36. Integrating general health care in private community psychiatry practice. Goff DC J Clin Psychiatry; 2007; 68 Suppl 4():49-54. PubMed ID: 17539701 [TBL] [Abstract][Full Text] [Related]
37. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness]. Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM; Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369 [TBL] [Abstract][Full Text] [Related]
38. Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Lett TA; Wallace TJ; Chowdhury NI; Tiwari AK; Kennedy JL; Müller DJ Mol Psychiatry; 2012 Mar; 17(3):242-66. PubMed ID: 21894153 [TBL] [Abstract][Full Text] [Related]
39. A potential role for adjunctive vitamin D therapy in the management of weight gain and metabolic side effects of second-generation antipsychotics. Nwosu BU; Meltzer B; Maranda L; Ciccarelli C; Reynolds D; Curtis L; King J; Frazier JA; Lee MM J Pediatr Endocrinol Metab; 2011; 24(9-10):619-26. PubMed ID: 22145446 [TBL] [Abstract][Full Text] [Related]
40. Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. Vitiello B; Correll C; van Zwieten-Boot B; Zuddas A; Parellada M; Arango C Eur Neuropsychopharmacol; 2009 Sep; 19(9):629-35. PubMed ID: 19467582 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]